Specialised Therapeutics Distributing Oncotype DX Breast Cancer Assay in Australia, New Zealand | GenomeWeb

NEW YORK (GenomeWeb News) – Biopharmaceutical firm Specialised Therapeutics Australia announced today a deal for the distribution of Genomic Health's Oncotype DX breast cancer assay in Australia and New Zealand.

Financial and other terms of the agreement, which took effect Jan. 1, were not disclosed.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Harold Varmus, a former NIH director, says that proposed reductions to the agency's budget are worrisome.

The Genome 10K project is to sequence about 10,000 vertebrate genomes, including ones of endangered species, Digital Trends reports.

The new Coalition to Save NIH Funding aims to educate lawmakers and the public on the significance of biomedical research.

In PLOS this week: analysis of viral sequences from human blood samples, gut microbiomes of heart failure patients, and more.